Skip to main content
Lippincott Open Access logoLink to Lippincott Open Access
editorial
. 2023 Dec 4;110(3):1331–1332. doi: 10.1097/JS9.0000000000000960

A commentary on ‘Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study’

Furui Zhong a, Chuanbo Xieb b, Xuefeng Peng a, Jinlong Luo a, Hua Yang a,*
PMCID: PMC10942231  PMID: 38051933

The combination of upfront pancreatectomy followed by adjuvant chemotherapy (AC) remains the established treatment for resectable pancreatic ductal adenocarcinoma (PDAC), as confirmed by several randomized trials13. In recent years, neoadjuvant chemotherapy (NAC) has gained attention as a viable treatment strategy for borderline resectable and locally advanced PDAC. This is due to its significant advantages in tumor downstaging, enhancing R0 resection rates, and ultimately improving overall survival (OS)4,5. However, limited and inconclusive evidence exists regarding the potential benefits of AC in patients undergoing pancreatic cancer resection following NAC. van Roessel et al.6 conducted a multicenter retrospective cohort study to address this issue, demonstrating that only patients with pathology-proven node-positive disease had improved survival when they received AC after NAC and pancreatic cancer resection. Subsequently, Sugawara et al.7 demonstrated a significant survival benefit associated with AC following NAC and resection in PDAC patients, consistent across various subgroups related to age, pathological T category, and resection margin.

In a recent article in the International Journal of Surgery, Pu et al.8 performed a retrospective, propensity-matched analysis using Surveillance, Epidemiology and End Results (SEER) data to evaluate the efficacy of AC in patients with resected pancreatic cancer after NAC. They included 1589 patients and concluded that systemic AC was associated with longer median OS (30.0 vs. 25.0 months, P=0.002) and cancer-specific survival (33.0 vs. 27.0 months, P=0.004) compared to the non-AC group. Subgroup analysis revealed that patients ≤65 years and those with node-positive disease (pathological N1 category) had a lower mortality when treated with AC. This large cohort study provides robust evidence supporting the clinical benefit of systemic AC in patients with resected PDAC after NAC.

Despite the propensity score matching, there are common issues associated with retrospective analysis of SEER data. First, as discussed, crucial data, such as surgical margin status and pathological response to multiagent NAC were unavailable. Indeed, patients who did not achieve an R0 resection and complete pathological response are more likely to receive AC post-surgery. All of these confounding factors have a significant correlation with patient prognosis, potentially impacting the study’s conclusions. Second, this study found that the OS benefit of AC was specifically observed in patients aged ≤65 years. This observation may be attributed to their superior performance status and chemotherapy tolerance. Performance status is a crucial predictor of postoperative mortality in various surgical procedures, yet this study lacks a corresponding indicator9. Moreover, data on postoperative complications are inadequate. Patients who experience postoperative complications are more likely to delay or even forgo AC, resulting in a worse prognosis. Finally, the time span of the included SEER data (2006–2019), would have certainly led to significant variations in treatment regiments. However, this study lacks detailed regimens and durations of NAC and AC, which severely limits the clinical generalizability of these findings.

Overall, we commend the authors for their remarkable efforts in assessing the survival benefit of systemic AC in patients undergoing NAC and resection. Considering the inherent limitations of SEER data, further prospective and large-scale studies targeting specific protocols and populations are necessary to confirm these findings.

Ethical approval

Not applicable for this study.

Sources of funding

This work was supported by key science and technology Project of Zigong (Nos.2022ZCYGY12).

Author contribution

F.Z.: study design and writing; C.X. and X.P.: critical review; H.Y.: study supervision.

Conflicts of interest disclosure

The authors declare that they have no conflicts of interest.

Research registration unique identifying number (UIN)

  1. Name of the registry: not applicable.

  2. Unique identifying number or registration ID: not applicable.

  3. Hyperlink to your specific registration (must be publicly accessible and will be checked): not applicable.

Guarantor

Furui Zhong and Hua Yang.

Footnotes

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Published online 4 December 2023

Contributor Information

Furui Zhong, Email: zfr0129@126.com.

Chuanbo Xieb, Email: 173474614@qq.com.

Xuefeng Peng, Email: 1270022403@qq.com.

Jinlong Luo, Email: ljl1990@126.com.

Hua Yang, Email: 851405328@qq.com.

References

  • 1. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379:2395–2406. [DOI] [PubMed] [Google Scholar]
  • 2. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011–1024. [DOI] [PubMed] [Google Scholar]
  • 3. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473–1481. [DOI] [PubMed] [Google Scholar]
  • 4. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:157–168. [DOI] [PubMed] [Google Scholar]
  • 5. Zou Y, Gao S, Yu X, et al. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study. Int J Surg 2023;109:1573–1583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment. JAMA Oncol 2020;6:1733–1740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Sugawara T, Rodriguez Franco S, Sherman S, et al. Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. JAMA Oncol 2023;9:316–323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Pu N, Wu W, Liu S, et al. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study. Int J Surg 2023;109:3137–3146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. George EL, Hall DE, Youk A, et al. Association between patient frailty and postoperative mortality across multiple noncardiac surgical specialties. JAMA Surg 2021;156:e205152. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Surgery (London, England) are provided here courtesy of Wolters Kluwer Health

RESOURCES